Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24960455 | 1.00 | CTSL (0.43) | CTSLCTSBCTSVCYP3A4CTSS | |
| SCHEMBL24960431 | 0.87 | CTSV (0.55) | CTSVCYP3A4CTSSCTSK | |
| SCHEMBL24691128 | 0.87 | CTSS (0.46) | CTSLCTSBCTSSCTSK | |
| SCHEMBL30001761 | 0.87 | CTSS (0.46) | CTSLCTSBCTSSCTSK | |
| SCHEMBL24960454 | 0.85 | CTSL (0.48) | CTSLCTSB | |
| SCHEMBL30001288 | 0.85 | CTSL (0.48) | CTSLCTSB | |
| SCHEMBL24113160 | 0.85 | — | — | |
| SCHEMBL29063090 | 0.85 | — | — | |
| SCHEMBL31374909 | 0.82 | CTSL (0.65) | CTSLCTSBCTSSCTSK | |
| SCHEMBL30819701 | 0.82 | CTSL (0.44) | CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347034-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117769541-A | protease inhibitors as antiviral agents | 艾森医药有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2022256434-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |